Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitory monoclonal antibodies

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• The erbB2 oncogene, a growth factor receptor, is overexpressed in aggressive tumors, correlating with poorer prognoses.
• Antibodies targeting erbB2 show variable antitumor effects, necessitating a deeper understanding of their interaction mechanisms.

Purpose of the Study:

• To elucidate the molecular basis of anti-erbB2 antibody interactions with the erbB2 ectodomain (ECD).
• To identify distinct binding epitopes for inhibitory and non-inhibitory antibodies, specifically Herceptin and HF.

Main Methods:

• Utilized computer-guided protein engineering and site-directed mutagenesis to analyze erbB2 ECD binding sites.
• Employed molecular docking, computer graphics, and distance geometry methods to identify interaction domains.
• Confirmed findings through studies on a series of erbB2 ECD mutants.

Main Results:

• Identified two distinct interaction domains on the erbB2 ECD for antibody binding.
• The non-inhibitory antibody HF recognized the N-terminal portion of the erbB2 ECD.
• The inhibitory antibody Herceptin exclusively bound to the C-terminal portion of the erbB2 ECD.

Conclusions:

• Antibody binding site on erbB2 ECD dictates inhibitory or non-inhibitory effects.
• The C-terminal region of erbB2 ECD, targeted by Herceptin, represents a significant target for developing novel anticancer therapies.